NKTR

Nektar Therapeutics

NKTR, USA

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

https://www.nektar.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NKTR
stock
NKTR

Nektar Therapeutics (Nasdaq: NKTR) to review 36-week REZOLVE-AA topline data Dec. 16 Stock Titan

Read more →
NKTR
stock
NKTR

Nektar Therapeutics (NASDAQ:NKTR) Stock Price Up 11% - Here's Why MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$107.2857

Analyst Picks

Strong Buy

2

Buy

2

Hold

3

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

9.06

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-41.75 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.79 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-414.55 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.54

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 42.51% of the total shares of Nektar Therapeutics

1.

Vanguard Group Inc

(4.0747%)

since

2025/06/30

2.

Nantahala Capital Management, LLC

(3.9644%)

since

2025/06/30

3.

Millennium Management LLC

(3.6252%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.927%)

since

2025/07/31

5.

AQR Capital Management LLC

(2.3899%)

since

2025/06/30

6.

BlackRock Inc

(2.3193%)

since

2025/06/30

7.

Balyasny Asset Management LLC

(2.1577%)

since

2025/06/30

8.

PRIMECAP Management Company

(1.6741%)

since

2025/06/30

9.

TCG Crossover Management, LLC

(1.4895%)

since

2025/06/30

10.

Renaissance Technologies Corp

(1.38%)

since

2025/06/30

11.

Woodline Partners LP

(1.3749%)

since

2025/06/30

12.

Susquehanna International Group, LLP

(1.2394%)

since

2025/06/30

13.

UBS Group AG

(1.1248%)

since

2025/06/30

14.

PRIMECAP Odyssey Aggressive Growth

(1.0547%)

since

2025/06/30

15.

Jacobs Levy Equity Management, Inc.

(0.828%)

since

2025/06/30

16.

22NW, LP

(0.8161%)

since

2025/06/30

17.

Geode Capital Management, LLC

(0.7394%)

since

2025/06/30

18.

Jain Global LLC

(0.7195%)

since

2025/06/30

19.

Boxer Capital Management, LLC

(0.6982%)

since

2025/06/30

20.

Armistice Capital, LLC

(0.6926%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6751%)

since

2025/07/31

22.

Eversept Partners, LLC

(0.6423%)

since

2025/06/30

23.

Vanguard Strategic Equity Inv

(0.5649%)

since

2025/06/30

24.

Emerald Growth A

(0.5038%)

since

2025/07/31

25.

PRIMECAP Odyssey Growth

(0.4281%)

since

2025/06/30

26.

DWS Small Cap Core S

(0.4189%)

since

2025/07/31

27.

Small Cap Core Equity Composite

(0.4189%)

since

2025/07/31

28.

Altium Capital Management, LP

(0.3915%)

since

2025/03/31

29.

Bridgeway Ultra-Small Company

(0.3694%)

since

2025/06/30

30.

BlackRock Advantage Small Cap Core Instl

(0.3676%)

since

2025/07/31

31.

Fidelity Extended Market Index

(0.3304%)

since

2025/07/31

32.

Principal SmallCap Growth I Instl

(0.3195%)

since

2025/07/31

33.

F/m Emerald Life Sciences Innovation ETF

(0.2944%)

since

2025/08/29

34.

Schwab US Small-Cap ETFâ„¢

(0.2844%)

since

2025/08/30

35.

Vanguard Strategic Small-Cap Equity Inv

(0.2842%)

since

2025/06/30

36.

Simplify Health Care ETF

(0.2838%)

since

2025/07/31

37.

Alger LIfe Sciences Innovation Composite

(0.2083%)

since

2025/06/30

38.

Fidelity Enhanced Small Cap ETF

(0.1821%)

since

2025/08/29

39.

Eastern Shore Small Cap Equity

(0.1813%)

since

2025/07/31

40.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0747%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.87

EPS Estimate

-0.1928

EPS Difference

-1.6772

Surprise Percent

-869.917%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.